Climb Bio Q3 net loss widens 13% to $14.57 million
CLYM•Climb Bio’s third-quarter 2026 net loss widened 13% year over year to $14.57 million, while research and development expenses rose 22% to $11.04 million. The company reported $227.6 million in cash, equivalents and marketable securities at September 30, with runway expected into the second half of 2028.
1. Quarterly results and pipeline
Climb Bio reported a third-quarter 2026 net loss of $14.57 million, up 13% year over year, and research and development expenses of $11.04 million, up 22%. Cash, cash equivalents and marketable securities totaled $227.6 million at September 30, with runway expected into the second half of 2028. CLYM116 Phase 2 dosing in IgAN began, with initial data expected in the first half of 2027; initial budoprutug Phase 2 pMN data showed immunologic remission at 200 mg, and additional cohort data are expected in 2027.
